Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »
Home2021Febbraio

Background: In advanced clinical decision support systems, patient characteristics and laboratory values are included in the algorithms that generate alerts. These alerts have a higher specificity than basic medication surveillance alerts. The alerts of advanced clinical decision support systems can be shown directly to the prescriber during order entry, without the risk of generating an overload of irrelevant alerts. We

Objective: The purpose of this study was to identify trends in oncology care that allow one to forecast workforce supply and demand, the training and skills needed by the oncology pharmacist for the likely future of oncology care. Methods: Interviews were conducted with experienced oncology pharmacists in leadership roles at 20 organizations balanced by geographic region and type of practice site

Purpose: Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non-small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact in advanced NSCLC with MET exon 14 skipping mutation or gene amplification. Materials and methods: Patients who participated in the screening of a phase II study of capmatinib for advanced NSCLC were enrolled in this study.

La produzione di letteratura medico-scientifica è in aumento e l’emergenza sanitaria causata dalla pandemia di CoViD-19 ha determinato un’ulteriore crescita del numero di articoli pubblicati ogni anno sulle riviste internazionali. Orientarsi in questo oceano di informazioni è molto difficile: la valutazione critica della documentazione scientifica richiede tempo e specifiche competenze, non facili da acquisire. Oltre ai medici e agli infermieri, anche

Objectives: The implementation of rapid diagnostic tests (RDTs) may enhance the efficiency of SARS-CoV-2 testing, as RDTs are widely accessible and easy to use. The aim of this study was to evaluate the performance of a diagnosis strategy based on a combination of antigen and IgM/IgG serological RDTs. Methods: Plasma and nasopharyngeal samples were collected between 14 March and 11 April

SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE21, and is a major antibody target. Here we report chronic SARS-CoV-2 with reduced sensitivity to neutralising antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences over 23 time points spanning 101 days. Little change was observed in the overall viral population structure

Since the early days of 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has become a global health concern. Currently, some therapies and vaccines have gotten the FDA approval or emergency use authorization (EUA) for the management of coronavirus disease 2019 (COVID-19). According to the pathophysiology of the disease, several medications have been evaluated in different clinical conditions

Background: Inclusion of productivity losses and gains in cost-effectiveness analyses for drugs is recommended by pharmacoeconomic guidelines in some countries and is considered optional in others. Often guidelines recommend analysis based on the payer perspective, but suggest that a supplemental analysis based on the societal perspective may be submitted that includes productivity losses/gains. However, there is no universally recognized framework